How Much Does Humira Cost in 2026, and Are Biosimilars Actually Cheaper?

Humira (adalimumab) held the title of the world's best-selling drug for over a decade, generating more than $20 billion per year in global revenue at its peak. It treats rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis by blocking tumor necrosis factor (TNF), a protein that drives inflammation. The drug is self-injected subcutaneously, typically every other week, but can also be administered in a clinical setting under provider supervision.

The US adalimumab market changed significantly starting in 2023 when AbbVie's patents expired and biosimilar competitors entered. As of 2026, more than 10 FDA-approved adalimumab biosimilars are on the market. At least seven carry the FDA's interchangeable designation (Amjevita, Cyltezo, Hyrimoz, Hulio, Simlandi, Yuflyma, and Abrilada), meaning a pharmacist can substitute them for Humira without a new prescription in most states. An unbranded adalimumab biosimilar from Boehringer Ingelheim is now available through GoodRx at approximately $550 for a two-pen carton, representing a 92% discount from Humira's list price. Despite this biosimilar competition, Humira's list price has not dropped significantly. Patients with Medicaid typically pay $1 to $4 in copays for adalimumab biosimilars when the drug is on formulary.

For patients who receive adalimumab in a doctor's office or infusion clinic, Medicare Part B covers the drug at ASP+6% under HCPCS code J0139 (injection, adalimumab, 1mg). Note: J0135 (per 20mg) was deleted effective January 1, 2025; any provider still using J0135 on 2025 or 2026 claims is using an invalid code. A standard 40mg dose equals 40 units of J0139. For patients who self-administer at home, the drug may fall under Medicare Part D, subject to the 2026 annual out-of-pocket cap of $2,100. Michigan price transparency data shows commercial hospital rates for the same monthly adalimumab regimen ranging from $1,200 to over $15,800 at facilities of comparable quality, a gap of more than $11,000. Seniors who qualify for both Medicare and Medicaid may receive Humira or a biosimilar through a dual-eligible benefit plan with minimal cost-sharing.

What Humira Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same humira can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

The Medicare ASP for a standard monthly adalimumab regimen (two 40mg doses) is approximately $1,853. Yet Michigan price transparency data shows commercial payer rates at facilities in the same metropolitan area ranging from under $2,000 to over $15,800 for the identical monthly treatment. The spread within a single metro area exceeds $11,000. This is not a difference in drug quality or purity. The drug molecule is identical whether it is administered at a community clinic or an academic medical center.

Hospitals apply what are called facility rates, which bundle drug acquisition cost with overhead: nursing administration, pharmacy handling, storage, and system-wide cost allocations. For a drug like adalimumab, the facility markup above Medicare ASP can be 4x to 8x. Henry Ford Health system's average commercial rate was $9,313 per monthly dose, which is more than four times the Medicare ASP. These markups translate directly to patient out-of-pocket costs at 20% coinsurance. A patient receiving adalimumab at a high-markup facility with 20% coinsurance could owe $1,863 per injection versus $185 per injection at a facility billing close to the Medicare rate.

The practical implication: choosing where you receive the injection matters as much as the drug itself. Hospital price transparency rules now require most facilities to publish negotiated rates, though enforcement remains inconsistent. If you receive adalimumab in a clinical setting, ask your provider or specialty pharmacy whether you can shift to a lower-cost outpatient facility or, if clinically appropriate, switch to home self-injection. Home self-injection at the Medicare rate rather than hospital outpatient billing can save thousands of dollars per year.

HCPCS J-Codes: What Appears on Your Bill

Adalimumab administered in a clinical setting (doctor's office, infusion suite, hospital outpatient) is billed under HCPCS Level II J-codes. Effective January 1, 2025, CMS deleted J0135 (per 20mg) and replaced it with J0139 (per 1mg). Any claim still using J0135 on or after January 1, 2025 is using an invalid code. These codes are public domain and appear on your Explanation of Benefits (EOB) or itemized bill:

Patient Assistance Programs

Several programs can reduce or eliminate adalimumab costs. Critical 2026 update: AbbVie is phasing out Humira from the myAbbVie Assist PAP. No new Humira applications are accepted after July 1, 2026. Patients currently enrolled may continue through their current eligibility term but cannot renew for Humira. AbbVie recommends biosimilar alternatives, many of which have their own cost-reduction programs:

Medicare Part D

Most Medicare patients receive adalimumab under Part B, because the drug is typically administered by a healthcare provider rather than purely self-administered. Under Part B, Medicare pays ASP+6% using J0139 (per 1mg) and the patient owes 20% coinsurance after the 2026 Part B deductible of $283. For a standard 40mg dose billed at $23.16 per mg, that is $927 per injection; the patient's 20% share is approximately $185 per injection, or about $370 per month for a twice-monthly regimen.

If you self-administer adalimumab at home and your Medicare Part D plan covers it, the 2026 annual out-of-pocket cap of $2,100 applies. There is no specific monthly cap for adalimumab under Part D (unlike insulin's $35/month cap). By 2026, most Medicare Part D formularies have shifted biosimilar adalimumab products to lower tiers and placed brand Humira at Tier 4 or 5 or removed it from the formulary entirely. An HHS OIG analysis of 2025 Medicare Part D plan formularies found that most plans covered adalimumab biosimilars. Check your plan's current formulary at Medicare.gov before filling a prescription, as a biosimilar at a lower tier can cost significantly less than brand Humira.

Common Humira Billing Errors

Adalimumab is a high-cost biologic with several documented billing error patterns. The 2025 HCPCS code change from J0135 to J0139 introduced new error risks. If your EOB or itemized bill shows unexpected charges, check for these before paying:

• Stale J0135 code on 2025 or 2026 claims: J0135 was deleted January 1, 2025. Any claim for a date of service on or after January 1, 2025 that shows J0135 should be resubmitted with J0139.
• Unit count error with J0139: A 40mg dose = 40 units of J0139 (not 2 units). If the bill shows J0139 x 2 units, the units are billed as if it were still J0135 at 20mg increments, which will cause underpayment claims and confusion. Verify: units billed x 1mg = total mg administered.
• Brand billed, biosimilar administered: your EOB shows Humira charges but the pharmacy dispensed Hadlima or Hyrimoz. The biosimilar should be billed at its own ASP rate, which differs from brand Humira's rate.
• Duplicate injection billing: two line items for the same date of service when only one dose was administered. Check that each J0139 line item corresponds to a distinct injection date.
• Facility fee added on top of an already-inflated drug charge: a separate facility fee for a routine office injection may not be warranted if it is bundled into the drug administration charge.

Frequently Asked Questions